"Every problem is an opportunity to find a
solution"
When using the ASRS-v1.1 Symptom Checklist for adults, in Part A, what number of checkmarks in darkly-shaded boxes are needed for a positive screen (symptoms highly consistent with ADHD and further investigation is warranted)?
4
What is Step 2 of the stepped approach to prescribing ADHD medications?
a) Ongoing follow-up
b) Medication selection
c) Titration and Monitoring
d) Setting treatment objectives
b) Medication selection
Name two strategies that can be used to optimize treatment when a patient’s goals of therapy are not being met.
Any two of the following (or any suggestions that fall into any of the categories below):
What are the benefits of long-acting stimulants?
a) Better adherence and convenience
b) Consistent, all-day symptom coverage
c) Reduced misuse and diversion
d) B & C
e) All of the above
e) All of the above
According to CADDRA (2020) Table 2.1, these are 3 of the most common psychiatric comorbidities in patients with ADHD.
Any 3 of the following:
Anxiety
Depression
Substance Use Disorder
Learning disorders
Borderline personality disorder
Up to ____ % of ADHD patients have at least one comorbid condition?
a) 35-40
b) 45-50
c) 65-70
d) 80-85
d) 80-85
This first line stimulant can be dosed up to 60 mg/day but no additional benefit was demonstrated at doses greater than 30 mg/day.
Vyvanse (lisdexamphetamine)
Which of the following is NOT considered second-line?
a) Ritalin SR
b) Guanfacine XR
c) Clonidine
d) Atomoxetine
c) Clonidine
**DAILY DOUBLE**
These are the names of the functional impairment scale & questionnaire for someone who knew the patient as a child.
WFIRS-S (Weiss Functional Impairment Rating Scale – Self) and SNAP-IV
Which one of these medications is considered amphetamine-based?
a) Biphentin
b) Foquest
c) Concerta
d) Vyvanse
d) Vyvanse
**DAILY DOUBLE**
Which of the following statements is TRUE about non-pharmacological treatments for ADHD:
a) Primary outcome is to ↓ core symptoms of ADHD (inattention, impulsivity, hyperactivity)
b) When used together with pharmacological treatment is more effective than either option alone and helps improve QoL
c) Helps target inattention better than pharmacological treatment
d) All of the above
b) When used together with pharmacological treatment is more effective than either option alone and helps improve QoL
Name two reasons why a drug holiday may be considered in an adult with ADHD.
Any two of the following:
List 3 specific life circumstances/scenarios associated with untreated ADHD that are NOT related to health comorbidities according to Chaulagain et al. (2023).
Any 3 of the following:
**DAILY DOUBLE**
Which stimulant indicated for adults has the longest duration of action?
a) Biphentin
b) Foquest
c) Concerta
d) Vyvanse
b) Foquest
Name 2 strategies to consider when a patient’s symptoms are due to rebound effect of the medication wearing off.
Any two of the following:
This study aimed to determine which medications were most effective and well-tolerated to help guide treatment decisions?
a) Cortese et al, 2018
b) Elliot et al, 2020
c) Oliveira et al, 2019
d) Rutledge-Jukes et al, 2024
a) Cortese et al, 2018
These are 3 of the 10+ areas of the brain that may be affected by ADHD (volume OR activation)
Any 3 of the following:
Smaller volumes in youth:
Less activation:
What was a limitation of the CADDRA 2020 guidelines?
a) Lack of transparency in linking evidence to recommendations
b) Lack of stakeholder involvement
c) Poorly defined scope and purpose
d) Not generally applicable to the ADHD patient population
a) Lack of transparency in linking evidence to recommendations
Which one of these statements is FALSE for patients with ADHD:
a) An ECG is recommended for all patients before prescribing a stimulant
b) An ECG is recommended for patients with hypertension before prescribing a stimulant
c) An ECG is recommended for patients with hypertension before prescribing atomoxetine
d) An ECG is recommended for all patients before prescribing modafinil
a) An ECG is recommended for all patients before prescribing a stimulant
**DAILY DOUBLE**
For a first line long-acting stimulant, efficacy for a given dose can be assessed in:
a) 2 days
b) 3-5 days
c) 1-3 weeks
d) 4-6 weeks
c) 1-3 weeks